^
    Back
    Association details:
    Biomarker:FGFR3 Y373C
    Cancer:Urothelial Cancer
    Drug Class:FGFR3 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASCO-GU 2021
    Title:

    Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

    Published date:
    02/08/2021
    Excerpt:
    Seven patients had confirmed activating hotspot FGFR3 mutations (p.S249C or p.Y373C)...3/7 patients with FGFR3 hotspot mutations received an FGFR2/3 inhibitor and none responded…
    DOI:
    10.1200/JCO.2021.39.6_suppl.472